Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E, Or R, Gan S, Shimoni A, Slavin S. Nagler A, et al. Among authors: ackerstein a. J Immunother. 2010 Apr;33(3):326-33. doi: 10.1097/CJI.0b013e3181c810b6. J Immunother. 2010. PMID: 20445353 Clinical Trial.
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
Or R, Ackerstein A, Nagler A, Amar A, Naparstek E, Varadi G, Kapelushnik J, Samuel S, Pugatsch T, Brautbar C, Slavin S. Or R, et al. Among authors: ackerstein a. J Immunother. 1998 Nov;21(6):447-53. doi: 10.1097/00002371-199811000-00007. J Immunother. 1998. PMID: 9807740 Clinical Trial.
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S, Ackerstein A, Or R, Shapira MY, Gesundheit B, Askenasy N, Morecki S. Slavin S, et al. Among authors: ackerstein a. Cancer Immunol Immunother. 2010 Oct;59(10):1511-9. doi: 10.1007/s00262-010-0878-1. Epub 2010 Jun 20. Cancer Immunol Immunother. 2010. PMID: 20563804 Free PMC article. Clinical Trial.
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Ben Shahar M, Slavin S. Morecki S, et al. Among authors: ackerstein a. Cancer Immunol Immunother. 1992;35(6):401-11. doi: 10.1007/BF01789019. Cancer Immunol Immunother. 1992. PMID: 1394343 Free PMC article. Clinical Trial.
69 results